Skip to main content
OpenTrials

Clinical trial condition

Communicable Diseases

Explore clinical trials studying Communicable Diseases. Study availability and eligibility vary by location and protocol.

9,174 public trials 549 recruiting studies
Refine in advanced search Browse all conditions

Communicable Diseases trial results

Completed

The Effectiveness of SMS in Improving Antiretroviral Medication Adherence Among Adolescents Living With HIV in Nigeria

NCT03394391

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • Lagos State University Teaching Hospital Ikeja, Lagos, Nigeria
  • The Nigerian Institute of Medical Research Yaba, Lagos, Nigeria
  • Federal Medical Center Abeokuta, Ogun State, Nigeria
  • State Hospital Ijebu Ode, Ogun State, Nigeria
View Trial Details
Completed

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

NCT00289731

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +12 more
Locations
  • GSK Investigational Site Wilrijk, Belgium
  • GSK Investigational Site Hradec Králové, Czechia
  • GSK Investigational Site Finsterwalde, Brandenburg, Germany
  • GSK Investigational Site Dresden, Saxony, Germany
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Dax, France
  • GSK Investigational Site Draguignan, France
  • GSK Investigational Site Essey-lès-Nancy, France
  • GSK Investigational Site Le Havre, France
View all 21 locations
View Trial Details
Completed

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

NCT00534638

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +22 more
Locations
  • GSK Investigational Site Kotka, Finland
  • GSK Investigational Site Kuopio, Finland
  • GSK Investigational Site Lahti, Finland
  • GSK Investigational Site Rauma, Finland
View Trial Details
Completed

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

NCT01249365

Conditions
Communicable Diseases, DNA Virus Infections, Disease Attributes, +11 more
Locations
  • GSK Investigational Site Parkville, Victoria, Australia
  • GSK Investigational Site Perth, Western Australia, Australia
  • GSK Investigational Site Almada, Portugal
  • GSK Investigational Site Coimbra, Portugal
View all 15 locations
View Trial Details
Completed

PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients

NCT01373684

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis B, +15 more
Locations
  • Toronto General Hospital Toronto, Ontario, Canada
  • Erasmus Medical Center Rotterdam, South Holland, Netherlands
  • Onze Lieve Vrouwen Gasthuis Amsterdam, Netherlands
  • VU university medical center Amsterdam, Netherlands
View Trial Details

Related conditions